NCCN Guidelines for Patients® Version Updates: Multiple Myeloma

NCCN Guidelines for Patients® Version Updates: Multiple Myeloma
Following are the major updates that were included in the NCCN Guidelines for Patients®: Multiple Myeloma, Version 1.2015.

Table of contents

  • Page 3
      • Part 3 is now called "Overview of myeloma treatments" instead of "Treatments for myeloma and its symptoms"
      • Part 5 is now called "Making treatment decisions" instead of "Deciding on a treatment plan"

Part 3 – Overview of treatmentstimes

  • Page 22 – Table of Contents
    • Treatments previously grouped together in "Local therapy" and "Systemic therapy" sections are now listed separately as:
      • "Radiation therapy"
      • "Surgery"
      • "Targeted therapy"
      • "Chemotherapy"
      • "Steroids"
    • "Side effects of cancer treatments" is no longer a separate section—the side effects of each treatment are now listed within each treatment section
  • Page 25 – Chart 3.1 "Drug treatments for multiple myeloma"
    • Added one new drug option: panobinostat

Part 4 – Treatment guide

  • Page 38 – Chart 4.2
  • – Primary treatment and follow-up for solitary plasmacytoma
    • Under "Follow-up tests":
      • Added the following recommendation: "Testing every 3 to 6 months"
  • Page 42 – Chart 4.4.1 – Primary treatment for active myeloma
    • This chart now includes primary treatment options for both transplant candidates and non-transplant candidates
  • Page 44 – Chart 4.4.2 – Follow-up after primary treatment for active myeloma
    • This chart now includes follow-up recommendations for both transplant candidates and non-transplant candidates
  • Page 50 – Chart 4.4.5 – Treatment for relapse or progressive disease after primary treatment
    • This chart is new and it includes recommendations for both transplant candidates and non-transplant candidates.
    • Under "Treatment options"
      • Added the following recommendation: "Testing every 3 to 6 months"
  • Page 51 – Chart 4.4.6 – Treatment for relapse or progressive disease after primary treatment
    • Under "Preferred regimens"
      • Added two new treatment options:
        • Panobinostat/bortezomib/dexamethasone, and
        • Carfilzomib/lenalidomide/dexamethasone

 

Part 5 – Making treatment decisions

  • Page 54 – Table of Contents
    • Added "Have a treatment plan" as a new section to replace "Benefits of a treatment plan" and "Parts of a treatment plan"
    • Added "Questions to ask your doctors" as a new section. The lists of questions were previously included at the end of each chapter.